MEDIDERM: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
MEDIDERM
Largest movements
- Receivables within one year +€33,389
up €33,389 (+69.9%), from €47,779 to €81,168
- Profit (loss) carried forward +€17,024
new in 2025: €17,024
- Tax, wage and social debts +€7,451
up €7,451 (+29.5%), from €25,266 to €32,717
- Other debts +€4,498
up €4,498 (+20.8%), from €21,641 to €26,139
- Trade debts +€4,110
new in 2025: €4,110
- Gross operating margin +€32,097
up €32,097 (+73.2%), from €43,860 to €75,957
- Taxes +€8,378
up €8,378 (+71.0%), from €11,793 to €20,171
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Cash bridge derived
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €67,932 | €101,014 | +€33,082 | +48.7% |
| Current assets | 29/58 | €67,932 | €101,014 | +€33,082 | +48.7% |
| Amounts receivable within one year | 40/41 | €47,779 | €81,168 | +€33,389 | +69.9% |
| Other amounts receivable | 41 | €47,779 | €81,168 | +€33,389 | +69.9% |
| Cash at bank and in hand | 54/58 | €16,677 | €15,964 | -€713 | -4.3% |
| Deferred charges and accrued income | 490/1 | €3,475 | €3,881 | +€406 | +11.7% |
| Total equity and liabilities | 10/49 | €67,932 | €101,014 | +€33,082 | +48.7% |
| Equity | 10/15 | €20,625 | €37,649 | +€17,024 | +82.5% |
| Contributions | 10/11 | €18,750 | €18,750 | = | 0.0% |
| Reserves | 13 | €1,875 | €1,875 | = | 0.0% |
| Distributable reserves | 133 | €1,875 | €1,875 | = | 0.0% |
| Profit (loss) carried forward | 14 | - | €17,024 | +€17,024 | |
| Amounts payable | 17/49 | €47,307 | €63,365 | +€16,059 | +33.9% |
| Amounts payable within one year | 42/48 | €46,907 | €62,965 | +€16,059 | +34.2% |
| Trade debts | 44 | - | €4,110 | +€4,110 | |
| Suppliers | 440/4 | - | €4,110 | +€4,110 | |
| Taxes, remuneration and social security | 45 | €25,266 | €32,717 | +€7,451 | +29.5% |
| Taxes | 450/3 | €25,266 | €32,717 | +€7,451 | +29.5% |
| Other amounts payable | 47/48 | €21,641 | €26,139 | +€4,498 | +20.8% |
| Accrued charges and deferred income | 492/3 | €400 | €400 | = | 0.0% |
| Other operating charges | 640/8 | €1,094 | €1,345 | +€252 | +23.0% |
| Gross operating margin | 9900 | €43,860 | €75,957 | +€32,097 | +73.2% |
| Operating profit (loss) | 9901 | €42,766 | €74,612 | +€31,846 | +74.5% |
| Financial income | 75/76B | €3 | - | -€3 | |
| Recurring financial income | 75 | €3 | - | -€3 | |
| Financial charges | 65/66B | €60 | €76 | +€16 | +26.5% |
| Recurring financial charges | 65 | €60 | €76 | +€16 | +26.5% |
| Profit (loss) for the period before taxes | 9903 | €42,709 | €74,536 | +€31,827 | +74.5% |
| Income taxes | 67/77 | €11,793 | €20,171 | +€8,378 | +71.0% |
| Profit (loss) for the period | 9904 | €30,915 | €54,365 | +€23,449 | +75.9% |
| Profit (loss) for the period to be appropriated | 9905 | €30,915 | €54,365 | +€23,449 | +75.9% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 9 October 2026 via checked.be.